The IGFBP-5 enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGFBP-5 in human serum and other biological fluids.
| Regulatory Status | For Research Use Only. Not for use in diagnostic or therapeutic procedures. |
|---|---|
| Packaging | 96 well microtiter |
| Detection | HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter |
| Dynamic Range | 6, 15.3-902 ng/mL |
| Limit of Detection | 4.4 ng/mL |
| Sample Size | 20 µL |
| Sample Type | Serum |
| Assay Time | 2 hours |
| Species Reactivity | Bovine, Canine, Equine, Human |
| Shelf Life | 24 months |
| Availability | Worldwide |
The IGFBP-5 ELISA is a quantitative two-step sandwich type immunoassay. In the first step, Calibrators, Controls and unknown diluted samples are added to IGFBP-5 antibody coated microtiter wells and incubated. After the first incubation and washing step, the wells are incubated with horseradish peroxidase labelled antibody conjugate. After a second incubation and washing step, the wells are incubated with substrate solution (TMB). After TMB incubation, an acidic stopping solution is added. In principle, the antibody-HRP conjugate binds to the solid phase antibody-antigen complex. Finally, the antibody-antigen and conjugate complex bound to the well is detected by addition of enzyme-substrate reaction. The degree of enzymatic turnover of the substrate is determined by dual wavelength absorbance measurement at 450 nm as primary test filter and 630 nm as reference filter. The absorbance measured is directly proportional to the concentration of IGFBP-5 in the samples and calibrators.
References:
1. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
2. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 – Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
3. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.
IGFBP-5 ELISA AL-127
Heitzeneder S, Shem J, Khan J, Mackall C. Pregnancy Associated Plasma Protein A (PAPP-A) Is A Novel Therapeutic Target In Ewing Sarcoma. Presented at 8th Ovarian Cancer Research; 2016 May 15-17; Niagra Falls, ON, Canada.
All Products Cited picoPAPP-A ELISA AL-101; Bioactive IGF-I ELISA AL-122; Total IGFBP-4 ELISA AL-126; Intact IGFBP-4 ELISA AL-128
Kumar A, Kalra B, Kommareddy V, Chowdavarapu K, Mistry S, Savjani G, Oxvig C. Development of Well Characterized ELISAs for Bound and Unbound Insulin-Like Growth Factors and their Binding Proteins. Poster presented at 98th Annual Endocrine Society Meeting; 2016 Apr 1-3; Boston, MA.
All Products Cited IGF-I ELISA AL-121; Bioactive IGF-I ELISA AL-122; IGF-II ELISA AL-131; IGFBP-2 ELISA AL-140; Intact IGFBP-3 ELISA AL-149, Total IGFBP-3 ELISA AL-120, Total IGFBP-4 ELISA AL-126, Intact IGFBP-4 ELISA AL-128, IGFBP-5 ELISA AL-127